timothy sykes logo
10x Genomics Stock Jumps As Analysts Hike Price Targets Thumbnail
G Google News

10x Genomics Stock Jumps As Analysts Hike Price Targets

ELLIS HOBBS•UPDATED AUG. 9, 2026, 11:06 AM ET
Reviewed by Matt Monacoand Fact-checked by Bryce Tuohey

10x Genomics Inc. stocks have been trading up by 13.62 percent following upbeat coverage of its single-cell sequencing innovations.

What Traders Need To Know

  • Q2 revenue came in at $151M versus roughly $146.6M–$146.7M expected, with EPS at -$0.14 versus an expected loss of about -$0.24 to -$0.26.
  • Management nudged 2026 revenue guidance up to $610M–$630M, slightly ahead of prior guidance and Street expectations around $613.7M.
  • Strong early demand for the Atera platform and a 74% gross margin signal improving unit economics despite a net loss.
  • Stifel doubled its TXG price target from $25 to $50 with a Buy rating, while Citi and Morgan Stanley raised targets to $50 and $40 but stayed Neutral/Equal Weight.
  • A new multi-year collaboration with Lausanne University Hospital (CHUV) puts TXG platforms at the center of advanced cancer diagnostics research.

Candlestick Chart

Weekly Update Aug 03 – Aug 07, 2026: On Sunday, August 09, 2026 10x Genomics Inc. stock [NASDAQ: TXG] is trending up by 13.62%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

10x Genomics holds a leading position in single-cell and spatial biology, with 6–14% multi‑year revenue CAGRs and Q2 revenue of $151M, annualizing near the guided $610–630M range. Gross margin near 70% and Q2’s 74% underscore strong pricing power, but EBIT and net margins remain negative and ROIC is deeply subscale. Balance sheet strength is a clear positive: minimal leverage (0.1x debt/equity), interest coverage effectively unlimited, and a ~6x current ratio with over $500M cash.

Technically, TXG has flipped into a sharp uptrend: the weekly tape shows a powerful reversal from the mid‑40s to a $52.25 high, with the $42.70 spike‑low followed by strong closes near the top of the range and expanding volume on up days. Short‑term, intraday 5‑minute candles show buyers consistently defending the $47–48 zone. Actionable level: $47 is key support; aggressive long entries $47–48 with a stop below $45 and upside toward the low‑ to mid‑50s.

Fundamentally, TXG is outgrowing most Healthcare tools peers and the broader Biotechnology & Life Sciences complex, aided by secular multiomics growth (~12% market CAGR), early Atera traction, and tightening 2026 guidance above Street. Multiple target hikes (Stifel to $50 Buy; Citi and Morgan Stanley inching higher) validate improving sentiment. With improving gross margins, ample cash, and strategic collaborations, fair near‑term value concentrates around $52–55; support sits near $45, resistance $55–57.

More Breaking News

Quick Financial Overview

10x Genomics Inc. just delivered a classic “beat but debate” quarter. Q2 2026 revenue was $151M, ahead of consensus around $146.6M–$146.7M, but only about 3% growth year over year on a like-for-like basis. EPS printed at -$0.14, better than the expected deeper loss, yet still a swing from a profit a year ago and a reminder that TXG is not in earnings power mode yet.

Under the hood, the story is tighter than the headline loss suggests. Gross margin improved to 74%, well above the 69.6% full-company gross margin in the ratio set, which tells you TXG’s core products are high-margin and scaling. Revenue over the last year was about $642.8M, with multi-year growth rates still solid, but profitability metrics like EBIT margin at -3% and profit margin around -3.6% show TXG is trading as a growth tools name, not a cash cow.

On the balance sheet, 10x Genomics Inc. looks financially sturdy for traders who worry about dilution and survival risk. Current ratio sits near 5.9, quick ratio around 5.1, and total debt-to-equity is very low at 0.1, backed by about $502.5M in cash and equivalents. Cash flow from operations of roughly $17.0M and free cash flow of about $15.4M in the latest quarter give TXG room to fund R&D and the Atera ramp without leaning on heavy borrowing.

The tape confirms how sensitive TXG is to catalysts. Weekly, the stock dropped from the mid-$40s to an intraday low near $42.70 around the earnings release before ripping to a high in the low $52s and closing the latest day near $51.81. That’s a big range, which day traders can’t ignore. Intraday, a wide 5-minute bar from roughly $45.51 to $52.22 with a close near $52.03 shows aggressive post-news buying after an initial shakeout.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”